Introdução Purinergic receptors, activated by extracellular ATP, are present in all tissue types and participate in physiological and pathophysiological processes. The P2Y2 receptor subtype is involved in numerous pathologies including Alzheimer´s diease, epilepsy, lung injury emphysema, cystic fibrosis and several types of cancer. A prominent function of this receptor is promotion of survival of tumor cells. In view of the lack of specific inhibitors for the P2Y2 receptor, the SELEX technique was used for developing high-affinity receptor blockers. | 
|
Objetivos
-Use the aptamer technology for developing high-affinity and specificity synthetic inhibitors for P2Y2 receptors.
- Use aptamers for P2Y2 receptor identification in tumor cells using cytometry techniques.
- Evaluate the potencial of anti-P2Y2 aptamers in blocking cancer cell proliferation and invasiveness.
- Study of aptamer effectiveness in blocking metastasis in preclininical mouse models transplanted with tumors.
- Safety tests and use anti-P2Y2 aptamers for tumor therapy in clinical trial
Aplicações e público alvo
- Research institutes for basic and translational applications.
- Pharmaceutical and drug-developing companies
- Hospitals working with pharmaceutic industry (clinical trials)
- Companies developing novel solutions for diagnostics
Estágio de desenvolvimento
Parceiros: FAPESP, CNPq, Universidade de São Paulo, Universidade Federal de São João del-Rei
Patente registrada sob n° PI11063122